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Introduction
MGMT is responsible of the elimination of alkyl groups from the O6-position of guanine; its promoter methylation results in diminished DNA-repair of O6-alkylguanine adducts and enhanced sensitivity to alkylating agents [1] [2] [3] [4] . After failure of initial studies with dacarbazine or temozolomide (TMZ) in all-comers with metastatic colorectal cancer (mCRC) [5] , recent phase II studies in the MGMT methylated subgroup showed an average response rate of 10% in chemorefractory disease [6] [7] [8] [9] [10] (supplementary Table S1 , available at Annals of Oncology online). Subsequent studies have been focused at improving such results by: (i) restricting the molecular selection to homogeneously MGMT hyper-methylated/ MGMT immunohistochemistry (IHC) negative tumors, (ii) bringing forward the use of TMZ in second-line treatment before the refractory setting (NCT02414009) and/or by adding TMZ to other active agents used in mCRC.
The role of chemotherapy reintroduction in mCRC patients with potential retained chemosensitivity to a specific agent has been mainly studied for oxaliplatin-based chemotherapy [11] . Conventionally, a chemotherapy-free interval of more than 3 months is adopted to assume potential disease sensitivity to specific agents used in previous treatment lines. The rationale for adding TMZ to irinotecan reintroduction (TEMIRI regimen) as salvage treatment of irinotecan-sensitive mCRC patients bearing MGMT methylation also relies on the synergy between topoisomerase II inhibitors and alkylating agents [12] and the need to improve the efficacy of each of these agents when used as monotherapy in later lines. In particular, successful treatment with TEMIRI plus bevacizumab had been reported in a refractory mCRC patient [13] .
Here, we hypothesized that TEMIRI salvage regimen may be a novel treatment option for pretreated irinotecan-sensitive mCRC patients with MGMT methylated and microsatellite stable (MSS) tumors.
Patients and methods

Study population
Key inclusion criteria were ECOG PS 0-1; at least two previous treatment lines for advanced disease (oxaliplatin-based adjuvant treatment was acceptable as a treatment line in case of disease relapse within 6 months); previous treatment with an anti-epidermal growth factor receptor monoclonal antibody if RAS (BRAF) wild-type disease and at least one antiangiogenic agent including bevacizumab, aflibercept and/or regorafenib; documented benefit (complete response, partial response or stable disease) from the last irinotecan-based regimen; irinotecan-free interval (IFI) defined as the time elapsed from the last administration of an irinotecan-based regimen to progressive disease (PD) >3 months, that is interruption of irinotecan-based therapy for reasons other than PD (>1 previous irinotecan-based line eligible); central confirmation on archival tumor tissue samples of MGMT methylation and MSS status by means of methylation-specific PCR (MSP) and multiplex PCR, respectively [8] . Key exclusion criteria were life-expectancy 12 weeks; inadequate liver, kidney and/or hematologic function; serious illness or medical conditions that contraindicated the treatment according to the investigators. All patients signed an Institutional Review Board-approved consent form (INT 20/13) before any study procedure.
Treatment schedule and study procedures
As shown in supplementary Figure S1 , available at Annals of Oncology online, patients received a maximum of six cycles of TEMIRI regimen (TMZ 150 mg/m 2 on days 1-5 plus irinotecan 100 mg/m 2 on days 1 and 15, every 28 days), followed by maintenance with single-agent TMZ at the same dose and schedule used in the combination phase, until PD, unacceptable toxicity or informed consent withdrawal. Radiological disease assessments were carried out at baseline and every 8 weeks until PD. Adverse events (AEs) and laboratory changes were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
Study end points
The primary end point of the study was overall response rate (ORR) according to RECIST v1.1 criteria. Secondary end points included clinical benefit rate (CBR), duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. Pre-specified exploratory end points included the correlation of activity/efficacy parameters with biomarkers, including MGMT IHC and Methyl-BEAMing (MB). IHC and MB analyses were carried out as described previously [9, 14] and patients were divided into IHC negative/low versus positive or according the MB cut-off of 63% identified previously [14, 15] , respectively.
Statistical design and analysis
TEMIRI treatment would have been judged promising for a hypothetical increase of ORR from 10% with TMZ alone [8] [9] [10] to 35% with TEMIRI regimen. According to the Fleming single-stage design and setting p0 (ORR in the null hypothesis) 0.10, and p1 (ORR in the alternative hypothesis) 0.35, a and b errors of 0.05 and 0.20, respectively, a total of 25 patients were required. Null hypothesis would have been rejected if RECIST response had been observed in at least six patients. Using the Kaplan-Meier method, PFS was calculated from the date of enrollment to the first event (i.e. disease progression or death from any cause) and OS from the date of enrollment to death or last follow-up. The Fisher's exact test was used to compare subgroups and variables.
Results
Patients' population
Between December 2014 and June 2017, 85 patients with irinotecan-sensitive mCRC were screened at two Italian institutions. Thirty-three patients (38%) had MGMT methylation by qualitative MSP assay. One patient died before the enrollment and seven were deemed not eligible for the trial (supplementary Figure S2 , available at Annals of Oncology online), until the target accrual of 25 patients was reached. Patients demographics and disease characteristics are shown in Table 1 . Notably, even if 17 (68%) patients had received 3 treatment lines, the median IFI was 6.8 (interquartile range, 4.4-12.8) months.
Treatment activity and efficacy
The primary end point of the study was met, since six patients achieved a confirmed partial response [ORR 24%, 95% confidence interval (CI) 11% to 43%]. CBR was 68% (95% CI 48% to 83%). Median DoR was 5.4 months (95% CI 0.7-8.3). One patient experienced rapid clinical deterioration and was not assessable for response. The waterfall and spider plots describing RECIST best responses and their dynamics are depicted in Figure  1A and B, respectively.
At a median follow-up of 15.6 (95% CI 10.2-21.3) months, 22 (88%) patients progressed and 15 (60%) died. Median PFS and OS were 4.4 (95% CI 2.9-8.3) and 13.8 (95% CI, 8.8-17.3) months, respectively (Figure 2A and B).
No significant differences in outcomes were observed according to best response (SD versus PR) to the last irinotecan-based regimen: in particular, ORR was 22% versus 20%, respectively (P ¼ 1.00).
Treatment safety
All patients that received at least one dose of treatment were evaluated for safety. Overall, the TEMIRI regimen was relatively well tolerated (Table 2) : only four (16%) patients had grade 3 or higher AEs and there were no treatment-related deaths. Three patients (12%) required a 25% reduction of irinotecan due to G3 pneumonia, protracted G1 hematologic toxicities and G2 gastrointestinal toxicities, respectively. One of them (4%) had also a 50% reduction of TMZ due to G3 diarrhea. Two patients (8%) started with a reduced irinotecan dose as per investigator decision, due to concomitant medical conditions. There were two treatment delays of more than 15 days due to a G3 pneumonia and G2 thrombocytopenia, respectively. Treatment was permanently interrupted in one case because of persistent G2 nausea and diarrhea.
Pre-specified exploratory biomarkers
Eighteen (72%) samples were classified by IHC as MGMT-low/ negative, whereas seven (28%) as MGMT-positive: 15 (60%) and 10 (40%) had an MB value 63% or <63%, respectively.
The association of MGMT IHC assessment and/or MB with ORR is described in supplementary Table S2 , available at Annals of Oncology online. A positive MGMT IHC was associated with a negative predictive value of 100% (7 out of 7 MGMT-positive patients were non-responders), while the positive predictive value of MGMT IHC was 33% (only 6 out of 18 patients with MGMT-negative/low achieved a response). The predictive accuracy of MGMT IHC was 52%. Regarding MB analysis, its negative and positive predictive values were 89% and 33%, respectively, with a predictive accuracy of 54%.
Regarding the impact of MGMT IHC on survival end points, patients with MGMT-negative/low tumors had a significantly longer median PFS (mPFS) than MGMT-positive ones [6.9 versus 2.0 months; hazard ratio (HR) ¼ 0.29, 95% CI 0.02-0.41; P ¼ 0.003; Figure 2C ], while no significant difference in terms of OS was observed (17.3 versus 13.8 months; HR ¼ 0.56, 95% CI 0.13-1.85; P ¼ 0.303; Figure 2D ). Similarly, patients with methylation percentage 63% by MB had a significantly longer mPFS than others (6.6 versus 3.8 months; HR ¼ 0.46, 95% CI 0.13-0.95; P ¼ 0.049; Figure 2E ), with no OS differences (15.5 versus 12.7 months; HR ¼ 0.75, 95% CI 0.24-2.11; P ¼ 0.327; Figure 2F ).
Neoantigen evolution during treatment
Interestingly, one MGMT IHC-negative, MSS, KRAS mutant female patient with initial RECIST response to TEMIRI underwent tumor re-biopsy at acquired resistance and Foundation One TM (Foundation Medicine, Inc., Cambridge, MA, USA) test was ordered on both archival and re-biopsy matching tumor samples. Mutational burden was estimated as high as 68 Muts/Mb only in the post-progression sample, whereas the expected non-hypermutated status (4 Muts/Mb) was confirmed in the archival sample. A BRCA2 E2198* somatic mutation emerged at acquired resistance, whereas mutations in mismatch repair genes did not even emerge at subclonal level (MSS status retained on both IHC and multiplex PCR).
Discussion
Life-expectancy of mCRC patients following the failure of second-line treatment is usually poor, particularly for RAS or BRAF mutated subgroups. Regarding the third-line treatment and beyond, two options are nowadays approved for chemorefractory disease: regorafenib and TAS-102. Such agents, however, confer a modest median OS gain of 1.4 and 1.8 months, respectively [16, 17] , with significant toxicities and financial burden. Even if breakthrough treatments are emerging for selected molecular subgroups, such as immunotherapy for microsatellite instability (MSI)-high [18] , dual HER2 blockade for HER2-positive [19] or entrectinib for ALK, ROS1 and NTRK1-3 fusion positive [20] mCRC patients, the individual prevalence of such predictive biomarkers is below 5%. Therefore, the majority of patients with mCRC are currently excluded from such promising options, highlighting the urgent need of active agents or regimens for pretreated patients.
MGMT methylation has emerged as a potential biomarker of response to alkylating agents in mCRC and several non-randomized clinical trials showed that the average ORR to TMZ is 10% in heavily pretreated patients [6, [8] [9] [10] . Additionally, given the evidence supporting chemo-holidays or maintenance strategies in the firstline setting, reintroduction of oxaliplatin-or irinotecan-based treatment-even if supported by retrospective data with low levels INT01  PI001  PI002  PI003  INT02  INT03  INT04  INT05  INT06  INT07  INT08  INT09  INT10  INT11  INT12  INT13  INT14  INT15  INT16  INT17  INT18  INT19  INT20 of evidence [11] -may be a reasonable option in individual patients carefully selected based on initial benefit, tolerability and chemotherapy-free intervals. The rationale for combining TMZ and irinotecan as salvage treatment of irinotecan-sensitive, MGMT methylated mCRC patients relies on two major points: (i) the unsatisfactory activity of single-agent TMZ in refractory patients with no proper molecular selection and (ii) the safety of the TEMIRI regimen, proven by several studies, even if with different schedules and dosages [21, 22] .
In our study, TEMIRI regimen achieved an ORR of 24%, mPFS and OS of 4.4 and 13.8 months, respectively, in heavily pretreated, carefully selected patients. Even if the activity of irinotecan/FOLFIRI was modest in second-line trials (4% to 16%) [23] [24] [25] , it must be pointed out that our patients were selected among those with clinically demonstrated chemosensitivity. However, our results suggest how TMZ and irinotecan may achieve synergistic rather than additive effects. In fact, based on the specific mechanisms of action of the two DNA-damaging agents, preclinical evidence showed that the inhibition of topoisomerase II enhances the cytotoxicity of alkylating agents [12] .
Even if our study was non-randomized and therefore TEMIRI regimen cannot be properly compared with other evidence-based options such as regorafenib or TAS-102, it must be pointed out that both agents achieved an ORR close to 0%, as well as a mPFS and OS of 1, 9 and 6, 4 months for regorafenib, and 2, 0 and 7, 1 months for TAS-102, respectively. Is there a way to improve the activity and efficacy of TMZbased therapy in mCRC patients bearing MGMT methylation? The extremely low positive predictive value of MSP has clearly shown that qualitative assessment of MGMT methylation is necessary but not sufficient to predict response to TMZ [8] [9] [10] . Besides the exclusion of the small fraction of patients with concomitant MSI-high status, which is putative of intrinsic resistance [26] , previous studies showed that absent or low MGMT IHC expression [9] , or high/homogeneous MGMT hyper-methylation [6, 14] may be associated with improved response to TMZ. Here, the easily available IHC analysis achieved the maximal negative predictive value since all patients with MGMT-positive tumors were non-responders. The lack of a formal statistical significance of our pre-planned exploratory biomarkers analysis for predicting treatment response may be due to both the small sample size and the relatively low positive predictive value. In fact, even if both IHC and MB (second-level analyses) outperformed MSP, they still had insufficient sensitivity to accurately predict TMZ response.
Finally, TMZ has gained a renewed attention for potentially novel therapeutic applications. In fact, while MSI-high glioblastoma is primarily resistant to TMZ, acquired resistance may also emerge through the induction of a MSI-like status [27, 28] . TMZ may induce an exponential increase of tumor mutational burden in MGMT-deficient melanoma or glioblastoma [29] [30] [31] . Based on such evidences, we recently showed that inactivation of DNA mismatch repair (MMR), driven by acquired resistance to TMZ, increased mutational load and promoted continuous renewal of neoantigens in human colorectal cancers while triggering immune surveillance in mouse models [32] . From this point of view, refining the prediction of TMZ response may be helpful in the next future to exploit treatment-induced hyper-mutational status as a potential target for immunotherapy strategies in selected patients. Namely, the emergence of high mutationalburden (and, as new report, an acquired BRCA2 mutation) in one patient confirms our previous report [32] and suggests that TMZ may be exploited as a priming agent to pharmacologically reshape the genetic and immunological landscape of MSS cancers, as will be tested by upcoming proof-of-concept clinical trials.
The biomarkers investigated here should be however considered as hypothesis-generating and, even if their effect on ORR and PFS suggest a predictive rather than prognostic value, the absence of a control group untreated with TMZ prevents from drawing conclusive results. Moreover, even the assessment of MGMT methylation itself should be considered investigational in the absence of randomized studies definitively demonstrating TMZ clinical effectiveness in molecularly selected mCRC patients.
In conclusion, TEMIRI is worth of investigation in randomized studies assessing the role of this regimen as compared with standard of care (such as regorafenib or TAS-102) in pretreated irinotecan-sensitive mCRC patients with MGMT methylation and absent/low MGMT immunohistochemistry protein expression. 
